Literature DB >> 25088197

Regulation of p21 by TWIST2 contributes to its tumor-suppressor function in human acute myeloid leukemia.

X Zhang1, W Ma1, J Cui2, H Yao2, H Zhou3, Y Ge4, L Xiao4, X Hu3, B-H Liu5, J Yang5, Y-Y Li5, S Chen6, C J Eaves7, D Wu6, Y Zhao1.   

Abstract

TWIST2 has a dual function in tumors. Its implication in the initiation and metastasis of various solid tumors is well established, and its tumor-suppressor role in murine osteosarcoma cells has been reported recently. However, the function of TWIST2 and its underlying mechanisms in human normal and malignant hematopoiesis remain unclear. In the present study, we found that TWIST2 directly regulated p21 in human hematopoietic cells and whose silence promoted cell proliferation and cell cycle progression. Hypermethylation of TWIST2 occurred to 23 out of the 75 adult acute myeloid leukemia (AML) patients and resulted in the impaired expression of both TWIST2 and p21. Conversely, TWIST2 overexpression inhibited the growth of AML cells partially through its direct activation of p21 with intact HLH (helix-loop-helix) domain. The microarray data and gene expression validation showed that TWIST2 was sufficient to activate known tumor-suppressor genes, whereas suppress known oncogenes, which further supported its inhibitory effect against AML cells. Taken together, our data have identified a novel TWIST2-p21 axis that modulates the cell cycle of both normal and leukemic cells and demonstrated that the direct regulation of p21 by TWIST2 has a role in its tumor-suppressor function in AML.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25088197     DOI: 10.1038/onc.2014.241

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  57 in total

1.  The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene.

Authors:  Cyril Duriez; Nicole Falette; Carole Audoynaud; Caroline Moyret-Lalle; Karim Bensaad; Stéphanie Courtois; Qing Wang; Thierry Soussi; Alain Puisieux
Journal:  Gene       Date:  2002-01-09       Impact factor: 3.688

2.  Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia.

Authors:  Erika Cosset; Ghassan Hamdan; Sandrine Jeanpierre; Thibault Voeltzel; Karen Sagorny; Sandrine Hayette; François-Xavier Mahon; Charles Dumontet; Alain Puisieux; Franck E Nicolini; Véronique Maguer-Satta
Journal:  Blood       Date:  2010-12-01       Impact factor: 22.113

3.  Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal.

Authors:  X Fang; Y Cai; J Liu; Z Wang; Q Wu; Z Zhang; C J Yang; L Yuan; G Ouyang
Journal:  Oncogene       Date:  2011-05-23       Impact factor: 9.867

4.  The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes.

Authors:  Xiang Li; A Mario Marcondes; Theodore A Gooley; H Joachim Deeg
Journal:  Blood       Date:  2010-06-18       Impact factor: 22.113

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  Mutations of the TWIST gene in the Saethre-Chotzen syndrome.

Authors:  V el Ghouzzi; M Le Merrer; F Perrin-Schmitt; E Lajeunie; P Benit; D Renier; P Bourgeois; A L Bolcato-Bellemin; A Munnich; J Bonaventure
Journal:  Nat Genet       Date:  1997-01       Impact factor: 38.330

7.  Homozygous nonsense mutations in TWIST2 cause Setleis syndrome.

Authors:  Turgut Tukel; Drazen Šošić; Lihadh I Al-Gazali; Mónica Erazo; Jose Casasnovas; Hector L Franco; James A Richardson; Eric N Olson; Carmen L Cadilla; Robert J Desnick
Journal:  Am J Hum Genet       Date:  2010-08-13       Impact factor: 11.025

8.  Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53.

Authors:  Koji Ueda; Hirofumi Arakawa; Yusuke Nakamura
Journal:  Oncogene       Date:  2003-08-28       Impact factor: 9.867

9.  The SCL relative LYL-1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation.

Authors:  Claude Capron; Yann Lécluse; Anna Lila Kaushik; Adlen Foudi; Catherine Lacout; Dalila Sekkai; Isabelle Godin; Olivier Albagli; Isabelle Poullion; Fedor Svinartchouk; Elisabeth Schanze; William Vainchenker; Fred Sablitzky; Annelise Bennaceur-Griscelli; Dominique Duménil
Journal:  Blood       Date:  2006-03-02       Impact factor: 22.113

10.  A twist code determines the onset of osteoblast differentiation.

Authors:  Peter Bialek; Britt Kern; Xiangli Yang; Marijke Schrock; Drazen Sosic; Nancy Hong; Hua Wu; Kai Yu; David M Ornitz; Eric N Olson; Monica J Justice; Gerard Karsenty
Journal:  Dev Cell       Date:  2004-03       Impact factor: 12.270

View more
  12 in total

Review 1.  The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome.

Authors:  Andrew D Redfern; Lisa J Spalding; Erik W Thompson
Journal:  Clin Exp Metastasis       Date:  2018-06-08       Impact factor: 5.150

2.  Up-regulation of SNHG6 activates SERPINH1 expression by competitive binding to miR-139-5p to promote hepatocellular carcinoma progression.

Authors:  Gang Wu; Xueming Ju; Youyu Wang; Zhixi Li; Xianfeng Gan
Journal:  Cell Cycle       Date:  2019-07-01       Impact factor: 4.534

3.  Growth arrest-specific protein 2 (GAS2) interacts with CXCR4 to promote T-cell leukemogenesis partially via c-MYC.

Authors:  Wenjuan Ma; Yan Wan; Jianxiang Zhang; Jianan Yao; Yifei Wang; Jinchang Lu; Hong Liu; Xiaorui Huang; Xiuyan Zhang; Haixia Zhou; Yulong He; Depei Wu; Jianrong Wang; Yun Zhao
Journal:  Mol Oncol       Date:  2022-09-11       Impact factor: 7.449

4.  Oncogenic heterogeneous nuclear ribonucleoprotein D-like modulates the growth and imatinib response of human chronic myeloid leukemia CD34+ cells via pre-B-cell leukemia homeobox 1.

Authors:  Dehuan Ji; Pengshan Zhang; Wenjuan Ma; Yiwen Fei; Wen Xue; Yu Wang; Xiuyan Zhang; Haixia Zhou; Yun Zhao
Journal:  Oncogene       Date:  2019-09-05       Impact factor: 9.867

Review 5.  Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?

Authors:  Lisa Pleyer; Peter Valent; Richard Greil
Journal:  Int J Mol Sci       Date:  2016-06-27       Impact factor: 5.923

Review 6.  Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic Implications.

Authors:  Nicola Stefano Fracchiolla; Bruno Fattizzo; Agostino Cortelezzi
Journal:  Stem Cells Int       Date:  2017-08-21       Impact factor: 5.443

Review 7.  EMT- and MET-related processes in nonepithelial tumors: importance for disease progression, prognosis, and therapeutic opportunities.

Authors:  Ulf D Kahlert; Justin V Joseph; Frank A E Kruyt
Journal:  Mol Oncol       Date:  2017-06-19       Impact factor: 6.603

8.  The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling.

Authors:  Dorian Forte; Valentina Salvestrini; Giulia Corradi; Lara Rossi; Lucia Catani; Roberto M Lemoli; Michele Cavo; Antonio Curti
Journal:  Oncotarget       Date:  2017-01-10

Review 9.  Emerging roles of epithelial-mesenchymal transition in hematological malignancies.

Authors:  San-Chi Chen; Tsai-Tsen Liao; Muh-Hwa Yang
Journal:  J Biomed Sci       Date:  2018-04-23       Impact factor: 8.410

10.  Smoking and gender modify the effect of TWIST on patient survival in head and neck squamous carcinoma.

Authors:  Yun Zhu; Wenjuan Zhang; Ping Wang
Journal:  Oncotarget       Date:  2017-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.